2021
DOI: 10.7759/cureus.20601
|View full text |Cite
|
Sign up to set email alerts
|

Role of Imaging Studies in Evaluating Patients Post Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

Abstract: A 77-year-old male presented to the ED with a new onset of acute abdominal pain, nausea, and vomiting. He had a previous surgical history of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for an appendiceal tumor. Despite the repeated reassuring abdominal examinations, CT abdomen showed high-grade bowel obstruction and perforation. He was urgently taken to the operating room and underwent resection of 70 cm segment of small ischemic bowel with primary anastomosis. His postope… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2022
2022

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 11 publications
0
1
0
Order By: Relevance
“…Peritoneal carcinomatosis used to be considered a palliative and incurable condition with poor survival rates [1] until 1995, when Sugarbaker et al standardized a surgical approach combined with locoregional chemotherapy, which enabled improvement in quality of life and survival [2]. Over the last decades, cytoreductive surgery (CRS) combined with hyperthermic intraoperative chemotherapy (HIPEC) has evolved as an effective multimodal treatment for selected patients with peritoneal surface malignancies of different origins [3][4][5][6][7]. As any complex procedure, it requires a multidisciplinary and dedicated team and a standard perioperative approach, which includes appropriate patient selection, preoperative optimization, intraoperative protocol, and adequate postoperative care to improve outcomes [8,9].…”
Section: Introductionmentioning
confidence: 99%
“…Peritoneal carcinomatosis used to be considered a palliative and incurable condition with poor survival rates [1] until 1995, when Sugarbaker et al standardized a surgical approach combined with locoregional chemotherapy, which enabled improvement in quality of life and survival [2]. Over the last decades, cytoreductive surgery (CRS) combined with hyperthermic intraoperative chemotherapy (HIPEC) has evolved as an effective multimodal treatment for selected patients with peritoneal surface malignancies of different origins [3][4][5][6][7]. As any complex procedure, it requires a multidisciplinary and dedicated team and a standard perioperative approach, which includes appropriate patient selection, preoperative optimization, intraoperative protocol, and adequate postoperative care to improve outcomes [8,9].…”
Section: Introductionmentioning
confidence: 99%